Current Studies
Clear Path Clinical Research is currently participating in three exciting clinical trials. Click on each trial below to learn more and explore the next steps for getting involved.
RECONNECT Study
Condition Evaluated: Postpartum Depression
This research study is evaluating RE104, an investigational drug, as a potential new treatment for mental health conditions including postpartum depression (PPD). RE104 belongs to a class of drugs called psychedelics.
​
After having a baby, some women get the “baby blues,” or feel sad, worried, or tired within a few days of giving birth. For many women, the baby blues go away in a few days. However, if any of the following symptoms persist for more than 2 weeks, this may be a sign of PPD.
​
-
Depressed mood is present most of the day
-
Loss of interest or pleasure, most of the day
-
Insomnia or sleeping too much
-
Unusually slow or fast movements
-
Feelings of worthlessness or guilt
-
Loss of energy or fatigue
-
Suicidal thoughts
-
Impaired concentration or indecisiveness
-
Change in weight or appetite​
Postpartum depression is a serious mental health condition that affects behavior and physical health. If you have PPD, the sad and hopeless feelings do not go away and may interfere with your day-to-day life.​ This study will compare a single dose treatment of 2 different strengths of RE104, a low dose (1.5 mg) and a high dose (30 mg). Study participants will be randomly assigned (like the flip of a coin) to receive one of the doses and neither they nor the Study Doctor will know which dose is given.
​
For more information or to enroll in the study, please click the button below.
Investigational TMS Study
Conditions Evaluated: Depression, Anxiety, Alzheimer’s Disease, and Insomnia Disorder
Clear Path Clinical Research is leading a new clinical trial to investigate the effects of an innovative Transcranial Magnetic Stimulation (TMS) device. “Investigational” means that the TMS device has not yet been approved by the U.S. Food and Drug Administration (FDA) for commercial use, but it is permitted for use in research studies. This study aims to explore how TMS may help improve symptoms in individuals living with a range of psychiatric and neurological conditions, including Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Alzheimer’s Disease (AD) and Insomnia Disorder (ID).
​
Transcranial Magnetic Stimulation (TMS) is a non-invasive, FDA-approved treatment for several mental health conditions. It works by delivering targeted magnetic pulses to specific regions of the brain, helping to regulate brain activity that may be underactive or overactive in certain disorders. While TMS is already approved for some conditions, this investigational study is evaluating a novel TMS device that could enhance treatment precision, offer new treatment protocols and increase treatment effectiveness for a broader range of conditions.
​
This clinical trial is designed to track and analyze several key areas that influence patient outcomes, including cognitive function, mood symptoms, anxiety symptoms, sleep quality, daily functioning and quality of life. Our goal is to better understand how this new TMS device may support individuals who have not found relief through traditional treatments, as well as those who are exploring treatment for the first time.
​
You may qualify for this study if you:
​
-
Are 12 years of age or older
-
Have a clinical diagnosis of one or more of the following:
-
Major Depressive Disorder (MDD)
-
Generalized Anxiety Disorder (GAD)
-
Alzheimer’s Disease (AD)
-
Insomnia Disorder (ID)
-
-
Are able to communicate in English
-
Can attend in-person sessions at our Seattle clinic
​
For more information or to enroll in the study, please click the button below.
TMS Long Term Durability Study
Condition Evaluated: Depression
This follow-up study is open to individuals who have completed our previous novel TMS study. The purpose of the study is to evaluate the long-term safety and effectiveness of an investigational stimulation protocol delivered through the Brainsway Deep TMS system. The term “investigational” indicates that this protocol has not been approved by the U.S. Food and Drug Administration (FDA) for general clinical use but may be used in research studies.
​
Participants will not receive additional TMS treatments. Instead, the study consists of follow-up assessments to monitor outcomes over time. Data will be collected at approximately 3, 6, 9, and 12 months after the completion of the initial treatment. Results from the investigational protocol will be compared to those from the standard FDA-approved Deep TMS protocol, with a key comparison point at six weeks post-treatment.
​
This study is for research purposes only and does not involve TMS treatment. Participation is limited to individuals who completed the initial TMS study.
​
For more information or to enroll in the study, please click the button below.